Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Jul 1;30(4):210-227.
doi: 10.4103/sjg.sjg_50_24. Epub 2024 May 16.

Eosinophilic esophagitis: Current concepts in diagnosis and management

Affiliations
Review

Eosinophilic esophagitis: Current concepts in diagnosis and management

Fahad I Alsohaibani et al. Saudi J Gastroenterol. .

Abstract

Eosinophilic esophagitis is an antigen-mediated chronic inflammatory disorder that has risen in incidence and prevalence over the past 2 decades. The clinical presentation is variable and consists of mainly esophageal symptoms such as dysphagia, heartburn, food impaction, and vomiting. Current management relies on dietary elimination, proton-pump inhibitors, and topical corticosteroids with different response rates and relapses after treatment discontinuation. With a better understanding of the underlying pathophysiology, many molecules emerged recently as targeted treatment including dupilumab (IL4/IL13 blocker), as the first FDA-approved biological treatment, which has changed the management paradigm.

PubMed Disclaimer

Conflict of interest statement

Evan S. Dellon, MD MPH

  1. Research funding: Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Eupraxia, Ferring, GSK, Meritage, Miraca, Nutricia, Celgene/Receptos/BMS, Regeneron, Revolo, Shire/Takeda

  2. Consultant: Abbott, Abbvie, Adare/Ellodi, Aimmune, Akesobio, Alfasigma, ALK, Allakos, Amgen, Aqilion, Arena/Pfizer, Aslan, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/BMS, Celldex, Eli Lilly, EsoCap, Eupraxia, Dr. Falk Pharma, Ferring, GSK, Gossamer Bio, Holoclara, Invea, Knightpoint, Landos, LucidDx, Morphic, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda, Target RWE, Upstream Bio

  3. Educational grant: Allakos, Aqilion, Holoclara, Invea.

The other authors reported no conflicts of interest related to this work.

Figures

Figure 1
Figure 1
Number of publications of EoE between 1978 and 2022
Figure 2
Figure 2
EoE is a chronic inflammatory condition of the esophagus which is allergen-driven, and its manifestation varies with age and could be provoked by either ingested food allergens or inhaled locally deposited aeroallergens. Although there is a genetic predisposition, environmental factors appear to have a larger role. Impaired epithelial barrier function with increased proteas activity, decreased junctional proteins, increased cellular proliferation (basal cell hyperplasia), and decreased differentiation. There is also an immune dysregulation with an increase in eosinophils, basophils, mast cells, and Th2 lymphocytes and an increase in IL-4, IL-5, and IL-13. These factors, in addition to the enhanced expression of TGF-β, result in activation of fibroblasts in the lamina propria, collagen deposition, and tissue stiffness. CCL 26: encodes eotaxin-3, CD4: cluster of differentiation 4, IL: interleukin, TGF-β: transforming growth factor beta, Th2: T helper 2 cell, TSP1: thrombospondin-1, TSPAN12: tetraspanin 12. Created by using pictures from Servier Medical Art. Servier Medical Art by Servier is licensed under a Creative Commons Attribution 3.0 Unported License (https://creativecommons.org/licenses/by/3.0/) and the figure was adapted from Underwood et al.[31]
Figure 3
Figure 3
Clinical presentations of EoE according to the age
Figure 4
Figure 4
Natural history of EoE if untreated
Figure 5
Figure 5
Endoscopic findings in EoE: a: Esophageal rings persisting in a patient with EoE on treatment. b: exudates and edema. c: Exudates, rings, edema, furrows, and mild narrowing. d: Crepe-paper mucosa after passing the scope in a narrowed proximal esophagus
Figure 6
Figure 6
EREFS endoscopic grading system for EoE[72] (Wolters Kluwer Health, Inc. Permission Licence Number 5720730303645)
Figure 7
Figure 7
Physiomechanical model of EoE. FLIP panometry outputs from six patients (A-F) with EoE are displayed reflecting the physiomechanical states of EoE. In A–C, esophageal distensibility is normal (noted by normal diameters of the esophageal body). In A, a normal contractile response involving repetitive antegrade contractions (RACs) is triggered, whereas B is weak with some evidence of contractions (BCR/IDCR with low bag pressures). C is nonreactive without triggering of contractility and can be achalasia-like (ALP) if the EGJ-DI >3.0 and Weak-GERD-like if EGJ-DI is >3.0. In D–F, fibrostenotic obstruction is reflected by reduced distensibilty (low diameters/reduced compliance) of the esophageal body and EGJ. In D, there is evidence of RACs with a rate of 6 and this pattern is associated with higher pressures than normal and a low EGJ-DI mechanical obstruction. Panel E shows reactive-spastic contractility patterns and is associated with spastic-like responses (IDCR/SRCR) and no evidence of RACs. The pressures in this pattern are usually well above 80 mmHg. F is nonreactive with absent contractile response, and the pressure is usually high, but does not have severe fluctuations like D and E (Image courtesy of Professor John E. Pandolfino, Chicago, IL, USA)
Figure 8
Figure 8
Treatment algorithm in patients with EoE

Similar articles

Cited by

References

    1. Velikova T. Challenges and updates in the management of eosinophilic esophagitis. Prz Gastroenterol. 2020;15:27–33. - PMC - PubMed
    1. Clayton F, Peterson K. Eosinophilic esophagitis: Pathophysiology and definition. Gastrointest Endosc Clin N Am. 2018;28:1–14. doi:10.1016/j.giec.2017.07.011. - PubMed
    1. O’Shea KM, Aceves SS, Dellon ES, Gupta SK, Spergel JM, Furuta GT, et al. Pathophysiology of eosinophilic esophagitis. Gastroenterology. 2018;154:333–45. - PMC - PubMed
    1. Straumann A, Spichtin HP, Bernoulli R, Loosli J, Vögtlin J. [Idiopathic eosinophilic esophagitis: A frequently overlooked disease with typical clinical aspects and discrete endoscopic findings. Schweiz Med Wochenschr. 1994;124:1419–29. - PubMed
    1. Landres RT, Kuster GG, Strum WB. Eosinophilic esophagitis in a patient with vigorous achalasia. Gastroenterology. 1978;74:1298–301. - PubMed

MeSH terms